
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : The fundings will be used to accelerate the development of Modulo’s first therapeutic program and its Modulo Neuroimmune Platform, to develop effective treatments for neurodegenerative disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2023
